Immunologic Predictors of Vaccine Responsiveness in Patients With Lymphoma and Chronic Lymphocytic Leukemia
- 4 March 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 230 (1) , 15-27
Abstract
Patients with B-cell lymphomas have altered cellular components of vaccine responses due to malignancy and therapy, and the optimal timing of vaccination relative to therapy remains unknown. Severe acute respiratory syndrome coronavirus 2 vaccines created an opportunity for new insights in vaccine timing because patients were challenged with a novel antigen across multiple phases of treatment. We studied serologic messenger RNA vaccine response in retrospective and prospective cohorts with lymphoma and chronic lymphocytic leukemia, paired with clinical and research immune parameters. Reduced serologic response was observed more frequently during active treatment, but nonresponse was also common within observation and posttreatment groups. Total immunoglobulin A and immunoglobulin M correlated with successful vaccine response. In individuals treated with anti-CD19–directed chimeric antigen receptor–modified T cells, nonresponse was associated with reduced B and T follicular helper cells. Predictors of vaccine response varied by disease and therapeutic group, and therefore further studies of immune health during and after cancer therapies are needed to individualize vaccine timing.Keywords
Funding Information
- Lymphoma Research Foundation
- Postdoctoral Fellowship Grant and Career Development Award
- Steve and Elizabeth Brodie Fund
- National Institutes of Health (P30-CA016520)
- National Institutes of Health (AI105343)
- National Institutes of Health (AI112521)
- National Institutes of Health (AI082630)
- National Institutes of Health (AI201085)
- National Institutes of Health (AI123539)
- National Institutes of Health (AI117950)
- Parker Institute for Cancer Immunotherapy
- University of Pennsylvania
- Lymphoma Research Foundation CDA
- Gilead Research Scholar Award
- Gabrielle's Angel Foundation for Cancer Research
- Emerson Collective Award
- Laffey-McHugh Foundation
- Berman and Maguire Funds
- Lymphoma Research at Penn (1K99CA212302)
- Lymphoma Research at Penn (R00CA212302)
- Doris Duke Charitable Foundation (2021190)
- Doris Duke Charitable Foundation (K08AI136660)
This publication has 42 references indexed in Scilit:
- Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple MyelomaClinical Lymphoma Myeloma and Leukemia, 2023
- Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccinationImmunity, 2021
- Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort StudyTransplantation and Cellular Therapy, 2021
- Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignanciesCancer Cell, 2021
- BNT162b2 COVID‐19 vaccine is significantly less effective in patients with hematologic malignanciesAmerican Journal of Hematology, 2021
- Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19Cell, 2020
- Vaccinations in patients with hematological malignanciesBlood Reviews, 2016
- Rituximab-Treated Patients Have a Poor Response to Influenza VaccinationJournal of Clinical Immunology, 2012
- Defining the human T helper 17 cell phenotypeTrends in Immunology, 2012
- Immunogenicity of Influenza Vaccination in Patients with Non-Hodgkin LymphomaJournal of Clinical Immunology, 2007